Galectin Therapeutics submits FDA registrational Phase 3 protocol for belapectin in MASH cirrhosis
Galectin Therapeutics submitted a registrational Phase 3 protocol to the FDA for belapectin to prevent disease progression in MASH cirrhosis with portal hypertension.